vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.
OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $8.6M, roughly 1.5× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -488.0%, a 512.8% gap on every dollar of revenue. On growth, Affinity Bancshares, Inc. posted the faster year-over-year revenue change (12.8% vs -22.4%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-57.1M). Over the past eight quarters, Affinity Bancshares, Inc.'s revenue compounded faster (8.1% CAGR vs -5.3%).
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
AFBI vs OCUL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $13.3M |
| Net Profit | $2.1M | $-64.7M |
| Gross Margin | — | 88.0% |
| Operating Margin | 35.9% | -526.5% |
| Net Margin | 24.9% | -488.0% |
| Revenue YoY | 12.8% | -22.4% |
| Net Profit YoY | 58.5% | -33.6% |
| EPS (diluted) | $0.34 | $-0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $13.3M | ||
| Q3 25 | $8.4M | $14.5M | ||
| Q2 25 | $8.3M | $13.5M | ||
| Q1 25 | $7.8M | $10.7M | ||
| Q4 24 | $7.6M | $17.1M | ||
| Q3 24 | $8.0M | $15.4M | ||
| Q2 24 | $8.3M | $16.4M | ||
| Q1 24 | $7.3M | $14.8M |
| Q4 25 | $2.1M | $-64.7M | ||
| Q3 25 | $2.2M | $-69.4M | ||
| Q2 25 | $2.2M | $-67.8M | ||
| Q1 25 | $1.8M | $-64.1M | ||
| Q4 24 | $1.3M | $-48.4M | ||
| Q3 24 | $1.7M | $-36.5M | ||
| Q2 24 | $1.0M | $-43.8M | ||
| Q1 24 | $1.3M | $-64.8M |
| Q4 25 | — | 88.0% | ||
| Q3 25 | — | 87.8% | ||
| Q2 25 | — | 85.6% | ||
| Q1 25 | — | 88.2% | ||
| Q4 24 | — | 92.8% | ||
| Q3 24 | — | 89.9% | ||
| Q2 24 | — | 90.8% | ||
| Q1 24 | — | 91.0% |
| Q4 25 | 35.9% | -526.5% | ||
| Q3 25 | 34.9% | -472.3% | ||
| Q2 25 | 34.1% | -502.6% | ||
| Q1 25 | 30.8% | -597.5% | ||
| Q4 24 | 21.1% | -296.1% | ||
| Q3 24 | 28.5% | -298.2% | ||
| Q2 24 | 16.2% | -265.1% | ||
| Q1 24 | 24.0% | -214.0% |
| Q4 25 | 24.9% | -488.0% | ||
| Q3 25 | 26.5% | -477.3% | ||
| Q2 25 | 25.9% | -503.9% | ||
| Q1 25 | 23.4% | -598.7% | ||
| Q4 24 | 17.7% | -283.3% | ||
| Q3 24 | 21.7% | -236.6% | ||
| Q2 24 | 12.5% | -266.3% | ||
| Q1 24 | 18.2% | -438.9% |
| Q4 25 | $0.34 | $-0.27 | ||
| Q3 25 | $0.34 | $-0.38 | ||
| Q2 25 | $0.33 | $-0.39 | ||
| Q1 25 | $0.28 | $-0.38 | ||
| Q4 24 | $0.21 | $-0.25 | ||
| Q3 24 | $0.26 | $-0.22 | ||
| Q2 24 | $0.16 | $-0.26 | ||
| Q1 24 | $0.20 | $-0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $737.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $654.3M |
| Total Assets | $881.7M | $808.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $737.1M | ||
| Q3 25 | $84.8M | $344.8M | ||
| Q2 25 | $89.7M | $391.1M | ||
| Q1 25 | $74.7M | $349.7M | ||
| Q4 24 | $41.4M | $392.1M | ||
| Q3 24 | $52.3M | $427.2M | ||
| Q2 24 | $50.4M | $459.7M | ||
| Q1 24 | $61.4M | $482.9M |
| Q4 25 | $127.0M | $654.3M | ||
| Q3 25 | $125.4M | $258.2M | ||
| Q2 25 | $124.1M | $305.9M | ||
| Q1 25 | $122.3M | $265.9M | ||
| Q4 24 | $129.1M | $315.3M | ||
| Q3 24 | $128.4M | $352.0M | ||
| Q2 24 | $125.1M | $377.7M | ||
| Q1 24 | $123.3M | $408.0M |
| Q4 25 | $881.7M | $808.1M | ||
| Q3 25 | $925.2M | $410.9M | ||
| Q2 25 | $933.8M | $451.3M | ||
| Q1 25 | $912.5M | $405.9M | ||
| Q4 24 | $866.8M | $457.9M | ||
| Q3 24 | $878.6M | $490.4M | ||
| Q2 24 | $873.6M | $517.1M | ||
| Q1 24 | $869.5M | $538.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-54.2M |
| Free Cash FlowOCF − Capex | $11.2M | $-57.1M |
| FCF MarginFCF / Revenue | 130.9% | -430.9% |
| Capex IntensityCapex / Revenue | 4.9% | 21.4% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | $-216.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-54.2M | ||
| Q3 25 | $3.7M | $-50.7M | ||
| Q2 25 | $3.8M | $-55.2M | ||
| Q1 25 | $1.9M | $-44.7M | ||
| Q4 24 | $6.8M | $-39.4M | ||
| Q3 24 | $4.1M | $-36.6M | ||
| Q2 24 | $619.0K | $-24.8M | ||
| Q1 24 | $1.2M | $-33.9M |
| Q4 25 | $11.2M | $-57.1M | ||
| Q3 25 | $3.6M | $-56.7M | ||
| Q2 25 | $3.7M | $-56.5M | ||
| Q1 25 | $1.8M | $-46.6M | ||
| Q4 24 | $6.4M | $-39.6M | ||
| Q3 24 | $4.0M | $-36.6M | ||
| Q2 24 | $489.0K | $-25.5M | ||
| Q1 24 | $1.1M | $-34.1M |
| Q4 25 | 130.9% | -430.9% | ||
| Q3 25 | 43.3% | -390.0% | ||
| Q2 25 | 44.0% | -419.7% | ||
| Q1 25 | 22.7% | -435.6% | ||
| Q4 24 | 83.9% | -232.0% | ||
| Q3 24 | 49.5% | -237.6% | ||
| Q2 24 | 5.9% | -155.4% | ||
| Q1 24 | 14.8% | -231.1% |
| Q4 25 | 4.9% | 21.4% | ||
| Q3 25 | 0.8% | 41.2% | ||
| Q2 25 | 1.4% | 9.3% | ||
| Q1 25 | 1.9% | 18.1% | ||
| Q4 24 | 5.6% | 1.2% | ||
| Q3 24 | 1.7% | 0.6% | ||
| Q2 24 | 1.6% | 4.5% | ||
| Q1 24 | 1.8% | 1.7% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
